It has been demonstrated that survivin, a novel member of the inhibitor of apoptosis (IAP) protein family, is expressed in human cancers but is undetectable in normal differentiated tissues. We employed a recombinant adenoviral vector (reAdGL3BSurvivin) in which a tumor-specific survivin promoter and a luciferase reporter gene were inserted into the E1-deleted region of adenovirus vector. Luciferase activity was measured in both multiple tumor cell lines and two primary melanoma cells infected with reAdGL3BSurvivin. Human fibroblast and mammary epithelial cell lines were used as negative controls. A reAdGL3CMV, containing the CMV promoter and luciferase gene, was used as a positive control to normalize the luciferase activity generated by the survivin promoter. Our data revealed that the survivin promoter showed high activity in both established tumor cell lines and the primary melanoma cells. In contrast, the in vivo studies indicated that the activities of survivin promoter were extremely low in the major mouse organs. The survivin promoter appears to be a promising tumor-specific promoter exhibiting a ''tumor on'' and ''liver off'' profile, and therefore, it may prove to be a good candidate for transcriptional targeting of cancer gene therapy in a wide variety of tumors.
T ranscriptional targeting of gene therapy is a strategy for enhancing the specificity of gene expression to target tumor cells of interest. This targeting approach is based on the use of tissue-or tumor-specific promoters (TSP) in a heterologous context to direct the expression of therapeutic genes specifically to the tumor. An efficient gene therapy regimen requires transgene expression in the tumor and absence of expression in relevant normal tissues, especially in the liver. This combination of ''tumor on'' and ''liver off '' profile can result in increasing the therapeutic index and limiting the toxicity of vectors and transgenes in vivo. Many promoters have already been evaluated for transcriptional targeting in cancer gene therapy, 1, 2 such as the a-fetoprotein (AFP) promoter for hepatic carcinoma, 3 the tyrosinase gene promoter for melanoma, 4 the prostate-specific antigen (PSA) promoter for prostate cancer, 5 and recently, the cyclooxygenase-2 (Cox-2) promoter for gastrointestinal cancer, 6 the midkine (MK) promoter for Wilms' tumor or neuroblastoma, 7 and the CXCR4 promoter for breast cancer and melanoma. 8 Presently, the data appear to show that transcriptional targeting can enhance the tumor specificity. However, the strategy described is not perfect and has disadvantages. For example, the novel CXCR4 promoter is over expressed in most breast cancers; 9 the CXCR4 gene has also been shown to be abundantly expressed in a variety of leukocytes, including peripheral blood lymphocytes, 10 monocytes, 11 pre-B cells, 12 and dendritic cells. 13 Thus, gene targeting using the CXCR4 promoter is directed to tumors as well as to normal host cells, and therefore impairs the host cells with different efficiencies.
Our goal is to search for a TSP that is expressed in a wide variety of tumors with a low expression in normal tissue. A novel gene, survivin, was recently identified by hybridization screening of human genomic libraries with the cDNA of a factor Xa receptor (EPR-1) 14 and might be a good candidate for this goal. Survivin is a novel member of the inhibitor of apoptosis (IAP) protein family, which plays an important role in the survival of cancer cells and the progression of malignancies. Members in the IAP protein family are generally characterized by one or more copies of the so-called baculovirus IAP repeat and by a ring finger domain at their carboxyl terminus. 15 The members of IAP family are thought to inhibit the terminal effector caspases directly through baculovirus IAP repeat (BIR)-dependent recognition. 16 At variance with the other IAP protein members, survivin has recently been characterized by a single baculovirus IAP repeat and no ring finger. 17, 18 The survivin gene is located on the long arm of human chromosome 17 at band 25, and contains four exons, which encode a 16.5 kDa protein. Survivin expression is found during embryonic and fetal development, 19 but is undetectable in terminally differentiated adult tissue. 20 Recently, various authors have described survivin messenger RNA expression in breast cancer, 21 pancreatic cancer, 22 esophageal carcinoma, 23 primary glioblastoma, 24 and ovarian cancer. 25 Therefore, the survivin promoter might be a good candidate to be used as a TSP in gene therapy approaches to cancers with a low-potential toxicity for normal host tissue in vivo.
Materials and methods

Cell lines and animals
The adenoviral transformed human embryonic kidney cell line, 293, was purchased from ATCC (Manassas, VA) and cultured in DMEM-F12 medium containing 10% FBS, 2 mM glutamine and penicillin (100 IU/ml)/streptomycin (100 mg/ml) at 371C in a humidified 5% CO 2 atmosphere. Three human ovarian cancer cell lines, SKOV3. ip1, OVCAR-3, and OV-4, two human breast cancer cell lines, MDA-MB-361, and DU4475, two pancreatic cancer cell lines, AsPC-1, and BxPC-3, and two melanoma cell lines, SK-MEL-28 and B16F10 (mouse), were used in this study. All of them were purchased from ATCC except for SKOV3.ip1 and OV-4, which were obtained from Janet Price (MD Anderson Cancer Center, Houston, TX) and Timothy J Eberlein (Brigham and Women's Hospital, Harvard Medical School, Boston, MA). Cells were cultured and propagated as recommended by the ATCC manual. A normal control human fibroblast cell (HFBC, a kind gift from Dr S Boppana, Children Hospital, UAB, Birmingham, AL) was cultured in MEM with 2 mM glutamine, 10% FBS and penicillin/streptomycin. After splitting, the cells were maintained in M199 with glutamine, supplemented with penicillin/streptomycin and 5% FBS. A human mammary epithelial cell line (HMEC) was used as a control and purchased from Cambrex BioScience (Walkersville, MD) and cultured in the medium specially purchased from the same company. Two primary melanoma cells, P-A and P-B, were kindly provided by Dr Detlef Dieckmenn. Cells were then cultivated for further experiments in RPMI containing 10% FCS, 20 mg/ml gentamicin (Sigma, Deisenhofen, Germany), and 2 mM glutamine. Cells were grown at 371C in a humidified atmosphere of 5% CO 2 .
Expression vectors and recombinant adenovirus
The recombinant adenovirus vectors that express firefly luciferase were constructed by homologous recombination in Escherichia coli using the AdEasy system. 26 All recombinant adenoviral vectors used in this study contain, in the E1-deleted region of the adenoviral vector backbone, a luciferase reporter gene, a simian virus 40 polyadenylation (SV40 poly-A) signal, and a promoter, such as the survivin, CMV or Cox-2M promoter, which drives the reporter expression. A clone, pLuc-cyc1. 2, 27 which contains an inserted 260 bp DNA fragment of the survivin promoter (À230 to þ 30), was used in this study. The survivin promoter region was excised with BamH I/ Hind III from this clone and subcloned into the PBS II SK( þ ) vector (Stratagene, La Jolla, CA) to generate PBSSK( þ )Survivin, which contains a 260 bp human survivin promoter. Then, a SacI/HindIII fragment from PBSSK( þ )Survivin was cloned into pGL3/Basic (Invitrogen, Carlsbad, CA) to generate pGL3BSurvivin. A KpnI/SalI fragment from this clone was subcloned into pShuttle vector (Quantum, Montreal, Quebec, Canada) to create pShuttleGL3BSurvivin. Subsequently, homologous recombination was performed with AdEasy (Quantum) in BJ5183 cells to create a new recombinant adenovirus, reAdGL3BSurvivin (Figure 1) , in which the luciferase reporter expression was driven by the survivin promoter.
Two control recombinant adenoviruses, AdGL3BCMV and AdGL3BCox-2M, are E1-and E3-deleted and express luciferase, which is induced by enhancer/CMV or the 942 bp Cox-2M promoter, 6 respectively. The viruses were propagated in the adenovirus-packaging cell line, 293, and purified by double CsCl density gradient ultracentrifugation, followed by dialysis against PBS with 10% glycerol. Physical particle concentration of virus (viral particles (vp)/ml) was determined by OD 260 reading, and biological activity (plaque-forming units, PFU/ml) was determined by standard plaque assay on 293 cells. Figure 1 Structures of the recombinant adenoviruses. AdGL3BSur-vivin was constructed by inserting a DNA fragment in E1-deleted region by KpnI/SalI restriction sites. This DNA fragment contains the 260 bp (À230 bp to þ 30 bp) the survivin promoter, as well as full length of luciferase cDNA, and simian virus 40 polyadenylation signal, the latter two from the vector, pGL3Basic (Promega). The recombinant adenovirus containing the survivin promoter was called reAdGL3BSurvivin. A control recombinant adenovirus, reAdGL3BCMV, is similar to AdGL3BSurvivin; the only difference is, instead of the survivin promoter, the CMV promoter was inserted in control reAd.
Gene expression detected by real-time quantitative PCR
Total cellular RNA was extracted from 5x10 5 cells of cell lines or primary melanoma cells using the RNeasy Mini kit (Qiagen, Valencia, CA), followed by treatment with RNase-free DNase to remove any possible contaminated DNA from the RNA samples. The fluorescent TaqMan probe (6FAM-TGACGACCCCATAGA-GGAACATAAAAAGCAT) and the primer pair (forward primer, TGGAAGGCTGGGAGCCA; reverse primer, GAAAGCGCAACCGGACG) used for real-time PCR in analysis of the survivin mRNA were designed using Primer Express 1.0 (Perkin Elmer, Foster City, CA), and synthesized by Applied Biosystems (Foster City, CA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. For real-time PCR assay, each 9 ml PCR reaction contained 3 mM MgCl 2 , 300 mM each dATP, dCTP, and dGTP, 600 mM dUTP, 100 nM of forward , reverse primers, and probe, 1 U of rTth DNA polymerase, 0.025% BSA, and RNase-free water. Plasmid standard or 1 ml of RNA sample was added into each assay tube. Negative controls with no template were performed for each reaction series. Real-time PCR reaction was carried out using a LightCycler TM System (Roche Molecular Biochemicals, Indianapolis, IN). Thermal cycling conditions were subjected to 2 minutes at 501C, 30 minutes at 601C, 5 minutes at 951C, then 40 cycles of 20 seconds at 941C, and 1 minute at 621C. Data were analyzed with Light Cycler software.
Analysis of the survivin promoter activity in vitro
For determination of transcriptional activity of the survivin promoter, 5 Â 10 4 cells of each established cancer cell line and normal control were plated in 24-well tissue plates and infected with reAdGL3BCMV or reAdGL3BSurvivin at MOI of 50 PFU/cell in 200 ml of individual growth medium containing 2% FBS (infection medium). The infection medium was replaced by a fresh medium containing 10% FBS after 3 hours. At 48 hours post infection, luciferase activity was determined using the Reporter Lysis Buffer and Luciferase Assay System of Promega (Madison, WI) following the manufacturer's protocol. Experiments were performed in triplicate and luciferase activities were standardized with relative light units (RLU) values of the CMV promoter (the CMV promoter activity is set at 100%).
Analysis of the survivin promoter activity in vivo
To analyze the survivin promoter transcriptional activity in mouse organs, C57BL/6 mice were injected with a dose of 5 Â 10 8 PFU of AdGL3BSurvivin or AdGL3BCMV via the tail vein. After 2 days, major organs, including the liver, lungs, kidneys, spleen, intestines, heart, and muscles, were harvested to measure luciferase expression. All the organs were rapidly frozen on dry ice and ground to a fine powder with a pestle and mortar in an ethanol/dry ice bath. The tissue powder was lysed with Cell Culture Lysis Buffer (Promega, Madison, MI) and after three rounds of freezing and thawing, samples were centrifuged to obtain the supernatant. The recovered supernatants were analyzed for luciferase activity with the Luciferase Assay System (Promega) on the Luminocount (Packard). Protein determination was performed by using Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Inc., Hercules, CA). Luciferase activities were normalized by protein levels.
Comparison of the transcriptional activity of the survivin promoter with that of the Cox-2M promoter in primary melanomas
The primary melanomas, P-A and P-B, were plated in 24-well plates at 5 Â 10 4 cells/well. Next day, cells were infected with reAdGL3BSurvivin, or reAdGL3BCox-2M at MOI of 50 PFU/cell in 200 ml of RPMI-1640 containing 2% FBS (infection medium). The infection medium was replaced by a fresh medium after 3 hours. At 48 hours after infection, luciferase activity was determined in the primary melanoma cells. In the primary melanoma cells and a normal cell line, HMEC, messenger RNA levels of the survivin gene were determined by real-time PCR.
Statistical analysis
The luciferase activities measured in this study were analyzed by t-test using Statistics Analysis Software 8.2. (SAS 8.2). A value of Po.05 was considered statistically significant.
Results
Survivin gene expression quantification in tumor cell lines by Real-Time PCR
To address the relevance of the candidate TSP, the survivin promoter, for different tumors, 10 cell lines, including two pancreatic cancer cell lines (BxPC-3, AsPC-1), two breast cancer cell lines (DU4475, MDA-MB-361), two ovarian cancer cell lines (OV4, SKOV3. ip1), two melanoma cell lines (SK-MEL-28, and a mouse melanoma cell line, B16F10), and two normal controls (HFB and HMEC) were performed by real-time PCR for survivin RNA level analysis. Real-time PCR and applied primers and probes were described in Materials and methods. The data of messenger RNA copy number, which were derived from cDNA by RT PCR from gene expression, are shown in Figure 2a . Three cell lines, MDA-MB361, SKOV3.ip1, and SK-MEL-28, expressed survivin messenger at high level; they are 35, 40.1, and 15.8 copies/mg total RNA. mRNAs in two pancreatic tumor cell lines, AsPC-1 and B Â PC-3, were detected at very low levels, same as the normal control cells, which had 1 and 1.2 copies/mg total RNA for HMEC and HFB, respectively. The remaining cell lines showed mid-level mRNA expression between 4 and 8.26 copies/mg total RNA. The data here revealed that not all tumors express a high level of survivin transcripts.
Analysis of the survivin promoter activity by adenovirus-mediated gene expression in vitro
To analyze the activity of the survivin promoter in an adenoviral-mediated gene expression context, cell lines were infected with recombinant adenovirus, reAdGL3BSurvivin or reAdGL3BCMV, in which the expression of the luciferase reporter gene was driven by the survivin promoter or the CMV promoter, respectively. The variations from each individual experiment (triplicate) were less than 5%. In Figure 2b , when comparing the survivin promoter activities to the CMV promoter activities in all cancer cell lines, luciferase activity driven by the survivin promoter was remarkably high in three cancer cell lines: melanoma, SK-MEL-28; breast, MDA-MB-361; and ovarian, OVCAR-3; 16.6% (P ¼ .0065), 14.5% (P ¼ .0005), and 11.7% (P ¼ .0028), respectively. The luciferase activities were moderately high in two pancreatic cancer cell lines, BxPC-3 and AsPC-1, and an ovarian cancer, SKOV3.ip1. They were 5.5% (P ¼ .005), 9% (P ¼ .001), and 8.4% (P ¼ .02) of that induced by the CMV promoter, respectively. In two normal control cell lines, HFBC and HMEC, the luciferase activities were 1.7% and undetectable, respectively. These data indicate that the survivin promoter has significantly higher transcriptional activity in most cancer cell lines examined in this study compared to that of control cell lines. Also, survivin mRNA levels in tumor cell lines (Fig 2a) basically correspond with the activities of survivin promoter in adenovirus vectors from in vitro experiments (Fig 2b) .
In vivo analysis of the survivin promoter activity in adenoviral context
To measure the activity of the survivin promoter in vivo, the recombinant adenoviruses, reAdGL3BCMV and reAdGL3BSurvivin, were administered intravenously to mice. The major organs, including liver, lungs, spleen, kidneys, heart, intestine, and muscles, were harvested 2 days following injection, and luciferase activity was determined as previously described. As demonstrated in Figure 3 , the CMV promoter activity was relatively high in the liver and spleen, and low in the kidneys and intestine. However, the survivin promoter activity was very low compared to that induced by the CMV promoter in all organs, especially in the liver and muscles. In liver, the mean luciferase activity with AdGL3BSurvivin (19,800 RLU/mg protein, n ¼ 5) was 0.07% of the activity of the CMV promoter. Lucifierase activity in the spleen of AdGL3BSurvivin-infected mice (126,396 RLU/mg protein, n ¼ 5) was 2.0% of AdGL3BCMV. The survivin promoter activity in the lung was 2.0% (629 RLU/mg protein, n ¼ 5) of the activity of AdGL3BCMV. Both activities of luciferase in the heart and kidneys were barely measurable in survivin-transfected animals, and were 0. and 2.0% of AdGL3BCMV (243 and 208 RLU/mg protein for AdGL3BSurvivin, n ¼ 5), respectively. In muscle, the survivin activity was 344 RLU/mg protein, and 0.08% of that produced by the CMV promoter. Although the survivin promoter activity ratio was high in the intestine, approximately 28% activity of AdGL3BCMV (776 RLU/mg protein for AdGL3BSurvivin, n ¼ 5), the absolute expression amount of the luciferase was only 3.9% of that of AdGL3BSurvivin in the liver. These data suggested that the expression of luciferase reporter gene driven by the survivin promoter was very low in mouse organs, and shows ''liver off '' status in vivo.
Activity of the survivin promoter in primary melanoma cells compared to that of the Cox-2M promoter
To further clarify survivin and Cox-2 function in a system that closely recapitulates the clinical situation, primary melanoma cells from two patients, P-A and P-B, were infected with reAdGL3BSurvivin or reAdGL3BCox-2M at MOI of 50 PFU/cell as previously described. Luciferase activity was determined 2 days postinfection. As demonstrated in Figure 4a , compared to the luciferase activity induced by the Cox2M promoter, the activity of the survivin promoter was increased 9.4-fold over that of the Cox-2M promoter in P-A primary melanoma cell culture, and 64-fold in P-B. The messenger RNA level of survivin gene was determined by real-time PCR in the two primary melanoma cells and in the negative control line (HMEC) in parallel. The data are shown in Figure 4b . Both primary melanoma cells show higher expression of survivin gene (1.4 copies/ng total RNA for P-A, and 31 copies/ng total RNA for P-B) than that of negative control, HMEC (0.29 copies/ng total RNA). Clearly, the messenger RNA levels of the survivin gene correlated with transcriptional activity of the survivin promoter in recombinant adenoviral context in two primary melanoma samples.
Discussion
A major theoretical rationale for developing molecular therapeutics in cancer is to achieve an improved therapeutic index. Adenoviral vectors are still widely used as gene transfer vectors in cancer therapy because of their ability to transfect a wide range of host tissues and also because of their ability to infect both proliferating and nonproliferating cells. These advantages of adenoviral vectors, however, result in a lack of specificity in their infection pattern leading to transfection of normal host tissues with an unfortunate accompanying potential for toxicity. To enhance the therapeutic index, attempts have been made to alter the tropism of viral vectors to achieve the required levels of efficiency and specificity. Transcriptional targeting methods have been studied that utilize TSPs to restrict transgene expression to tumor cells. 6, 7 A wide range of promoters have been evaluated for transcriptional targeting. These results leave no doubt that transcriptional targeting can enhance the tumor specificity and therapeutic index. However, the weakness of currently available promoters is that TSPs, despite their name, lack sufficient specificity to avoid expression in normal tissues. Thus, a continued search for a true TSP, which is expressed at high levels in tumor cells and at low levels in normal host cells, is warranted.
In the present study, we explored the survivin gene promoter as a candidate TSP in order to restrict adenoviral transgene expression specifically to tumor cell lines. The survivin gene is a member of the IAP protein family, which plays an important role in the growth and progression of a variety of cancers. Recently, the survivin gene has been described as being selectively expressed in some of the most common human neoplasms as described above, and survivin expression is correlated with clinical progression, 28, 29 and resistance to chemo-and radiotherapy. 30 A possible mechanism of enhanced tumor survival with high levels of survivin has been suggested to involve modulation of the apoptosis pathway, 31, 32 and may depend on inhibition of the two early apoptotic enzymes caspase-3 and caspase-7, 33 thus preventing programmed cell death. This mechanism is supported by the observation that downregulation of survivin expression by induction of the effector cell protease receptor-1 (EPR-1) enhances apoptosis, reduces tumor growth potential, and results in an increased sensitivity to anticancer agents. 34 Recently, the survivin protein has been identified on the basis of spontaneous CTL responses in different cancer patients, and thus it may serve as a molecular target for anticancer immunotherapy. 35 These credentials suggest that survivin could, in principle, be a rational target for cancer therapies, and might be a universal tumor antigen. In this study, the activity of survivin promoter in the context of adenoviral vector-mediated gene expression was significantly higher (Po.01) in three different cancer cell lines, including breast (MDA-MB-361), ovarian (OVCAR-3), and melanoma (SK-Mel-28) (14.1, 11, and 16.7% of that induced by the CMV promoter, respectively) than that measured in non-neoplastic control cells. The other cell lines, including an ovarian, SKOV3.ip1, and two pancreatic tumor lines (AsPC-1, BxPC-3), moderately increased transgene expression driven by the survivin promoter (8.4% (P ¼ .02), 9% (P ¼ .001), and 5.7% (P ¼ .005) of that driven by the CMV promoter, respectively) compared to control. These data clearly show that the survivin promoter is ''tumor on'' in in vitro experiments not only for a one specific tumor, but also for multiple tumors. The obvious implication is that the survivin promoter is a good TSP with significant ability to drive transgene expression in multiple cancer cell lines. However, in a mouse melanoma cell line, B16F10, which readily metastasizes to lung, transgene expression (4.2%) induced by the survivin promoter was slightly high compared to that of controls. Therefore, there might be no significant correlation between the survivin promoter activity and metastatic level. In addition, we observed low activity of the survivin promoter in a healthy control cell, HFBC, although most previous reports described that the survivin gene is not expressed in normal tissues. In addition to tumor selectivity, the promoter is required to have ''liver off '' status in vivo, because adenoviruses mainly localize to the liver when systemically administered. This could lead to severe liver dysfunction. 36 Previous studies 20 reported that the survivin protein was not detected by Western blot in most normal adult mouse tissues including liver. However, the thymuses are slightly positive for survivin expression. In our experiments, mice that received luciferase-expressing adenoviral vectors showed that the luciferase expression in liver was very low, only 0.07% of that with the CMV promoter. Further, the activity of the survivin promoter was low in other organs as well. In spleen, lungs, heart, kidneys, and muscle, the activities of survivin promoter were 2.1, 2.1, 0.1, 2, and 0.08% of the CMV promoter, respectively. Although luciferase activity was 28.1% of the CMV promoter in intestine, the absolute value in intestine was only less than 4% of that in liver. These results indicate that the survivin promoter has a ''liver off '' status in vivo and has a very low background of transcriptional activity in major mouse organs. Therefore, this promoter may be useful for gene therapy approaches because of its very low induction of transgene in normal tissues, which minimizes the potential toxicity to host cells.
In our analysis using established cell lines, the activity of the survivin promoter in an Ad construct was remarkably high in multiple cancer cell lines as described above, compared to that of the CMV promoter. However, a discrepancy between gene transfer efficiencies in cancer cell lines and clinical trials has been described to exist. 37 Therefore, to further test promoter function in a system that closely recapitulates the in vivo situation, experiments were performed to evaluate these promoters in primary tumor cells from patients. Dr Nettelbeck et al 38 recently demonstrated that the activity of the Cox-2 promoter in melanoma cells was high, but not in nonmalignant primary dermal melanocytes. Thus, they concluded that the tumor-specificity of the Cox-2 promoter can be utilized for transcriptional targeting application of adenoviral vector-based gene therapy or oncolysis to melanoma. On this basis, we compared the transcriptional activity of the survivin promoter to that of the Cox-2 promoter in primary melanoma cells from two patients. The results clearly show that the activities of the survivin promoter in two melanoma patients were 9.4-and 64-fold higher than that of the Cox-2M promoter, respectively. These results were correlated with the data produced by real-time PCR, which showed that the survivin mRNA levels in two patients were 1.4 and 31 copies/ng total RNA, respectively, compared to that of 0.29 copies/ng total RNA in normal cell lines, HMEC. Thus, the survivin promoter appears to be a more powerful TSP for melanomas than the Cox-2 promoter.
In conclusion, the activity of the survivin promoter is high in a wide range of tumors, and low in liver and other normal major organs. This promoter is therefore a promising candidate for tumor-specific gene therapy applications for melanoma and may prove to be an excellent TSP for a variety of other tumors as well.
Abbreviations bp, base pairs; CMV, cytomegalovirus; Cox-2, cyclooxygenase 2; MOI, multiplicity of infection; PFU, plaqueforming units; vp, viral particles; TSP, tumor-specific promoter.
HL67962, K12 HD01261-02 (WRHR) 5P50 CA83591 (Ovarian SPORE Developmental Grant.
